
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5511727/publications.pdf Version: 2024-02-01



MICAELA EDEDI

#	Article	IF	CITATIONS
1	Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Research and Therapy, 2012, 14, R97.	1.6	124
2	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 247 consecutive cases. Autoimmunity Reviews, 2015, 14, 387-395.	2.5	121
3	Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera. Journal of Immunological Methods, 2016, 433, 1-5.	0.6	109
4	Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus. Arthritis Care and Research, 2017, 69, 115-123.	1.5	107
5	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. Autoimmunity Reviews, 2019, 18, 406-414.	2.5	106
6	Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study. Autoimmunity Reviews, 2016, 15, 983-993.	2.5	105
7	Myositis autoantibodies and clinical phenotypes. Autoimmunity Highlights, 2014, 5, 69-75.	3.9	95
8	Neutrophil Extracellular Traps Profiles in Patients with Incident Systemic Lupus Erythematosus and Lupus Nephritis. Journal of Rheumatology, 2020, 47, 377-386.	1.0	77
9	Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome. Journal of Autoimmunity, 2012, 38, J197-J208.	3.0	69
10	Systemic lupus erythematosus: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000793.	1.8	66
11	Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis. Clinical and Experimental Rheumatology, 2014, 32, 891-7.	0.4	66
12	A comprehensive review of the clinical approach to pregnancy and systemic lupus erythematosus. Journal of Autoimmunity, 2016, 74, 106-117.	3.0	62
13	Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real‣ife Setting. Arthritis and Rheumatology, 2020, 72, 1314-1324.	2.9	58
14	Clinical Significance of IgA Anti-Cardiolipin and IgA Anti-β2Glycoprotein I Antibodies. Current Rheumatology Reports, 2013, 15, 343.	2.1	53
15	Longterm Outcome of Patients with Primary Antiphospholipid Syndrome: A Retrospective Multicenter Study. Journal of Rheumatology, 2017, 44, 1165-1172.	1.0	51
16	Aicardi–Goutieres syndrome, a rare neurological disease in children: A new autoimmune disorder?. Autoimmunity Reviews, 2013, 12, 506-509.	2.5	50
17	Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years. Lupus, 2017, 26, 1197-1204.	0.8	50
18	Systemic vasculitis and pregnancy: A multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies. Autoimmunity Reviews, 2015, 14, 686-691.	2.5	46

#	Article	IF	CITATIONS
19	Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis. Clinical Rheumatology, 2017, 36, 469-475.	1.0	45
20	Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. Autoimmunity Reviews, 2019, 18, 164-176.	2.5	44
21	First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry). Frontiers in Cardiovascular Medicine, 2019, 6, 11.	1.1	39
22	Rare autoantibodies to cellular antigens in systemic lupus erythematosus. Lupus, 2014, 23, 672-677.	0.8	35
23	Risk Factors for Adverse Maternal and Fetal Outcomes in Women With Confirmed aPL Positivity: Results From a Multicenter Study of 283 Pregnancies. Frontiers in Immunology, 2018, 9, 864.	2.2	34
24	Primary Biliary Cirrhosis-related Autoantibodies in a Large Cohort of Italian Patients with Systemic Sclerosis. Journal of Rheumatology, 2011, 38, 2180-2185.	1.0	33
25	Triple Antiphospholipid (aPL) Antibodies Positivity Is Associated With Pregnancy Complications in aPL Carriers: A Multicenter Study on 62 Pregnancies. Frontiers in Immunology, 2019, 10, 1948.	2.2	33
26	Systemic Lupus Erythematosus and Endothelial Dysfunction: A Close Relationship. Current Rheumatology Reviews, 2019, 15, 177-188.	0.4	27
27	Typing TREX1 gene in patients with systemic lupus erythematosus. Reumatismo, 2015, 67, 1-7.	0.4	26
28	The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies. Clinical Reviews in Allergy and Immunology, 2017, 52, 88-98.	2.9	26
29	Should we treat congenital heart block with fluorinated corticosteroids?. Autoimmunity Reviews, 2017, 16, 1115-1118.	2.5	25
30	Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study. Journal of Autoimmunity, 2021, 116, 102545.	3.0	25
31	Neutrophil Extracellular Traps in the Autoimmunity Context. Frontiers in Medicine, 2021, 8, 614829.	1.2	25
32	Antiphospholipid antibodies mediate autoimmunity against dying cells. Autoimmunity, 2013, 46, 302-306.	1.2	24
33	Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis. Clinical Reviews in Allergy and Immunology, 2021, 60, 87-94.	2.9	24
34	Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort. Journal of Autoimmunity, 2021, 124, 102729.	3.0	23
35	Classification of primary antiphospholipid syndrome as systemic lupus erythematosus: Analysis of a cohort of 214 patients. Autoimmunity Reviews, 2018, 17, 866-872.	2.5	22
36	Exploring Autoimmunity in a Cohort of Children with Genetically Confirmed Aicardi–Goutières Syndrome. Journal of Clinical Immunology, 2016, 36, 693-699.	2.0	21

#	Article	IF	CITATIONS
37	Endothelial Dysfunction in Early Systemic Lupus Erythematosus Patients and Controls Without Previous Cardiovascular Events. Arthritis Care and Research, 2018, 70, 1277-1283.	1.5	21
38	The clinico-serological spectrum of overlap myositis. Current Opinion in Rheumatology, 2018, 30, 637-643.	2.0	20
39	Celiac Disease Prevalence Is Increased in Primary Sjögren's Syndrome and Diffuse Systemic Sclerosis: Lessons from a Large Multi-Center Study. Journal of Clinical Medicine, 2019, 8, 540.	1.0	20
40	Macrophage activation syndrome in adult systemic lupus erythematosus: report of seven adult cases from a single Italian rheumatology center. Reumatismo, 2018, 70, 100-105.	0.4	19
41	C9orf72 Intermediate Alleles in Patients with Amyotrophic Lateral Sclerosis, Systemic Lupus Erythematosus, and Rheumatoid Arthritis. NeuroMolecular Medicine, 2019, 21, 150-159.	1.8	19
42	Anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus patients with articular involvement: a predictive marker for erosive disease?. Reumatismo, 2012, 64, 321-5.	0.4	18
43	IRF5 is associated with primary antiphospholipid syndrome, but is not a major risk factor. Arthritis and Rheumatism, 2010, 62, 1201-1202.	6.7	17
44	Relationship between endothelial dysfunction, videocapillaroscopy and circulating CD3+CD31+CXCR4+ lymphocytes in systemic lupus erythematosus without cardiovascular risk factors. Lupus, 2019, 28, 210-216.	0.8	17
45	Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis. Rheumatology, 2022, 61, 688-695.	0.9	17
46	Low Preconception Complement Levels Are Associated with Adverse Pregnancy Outcomes in a Multicenter Study of 260 Pregnancies in 197 Women with Antiphospholipid Syndrome or Carriers of Antiphospholipid Antibodies. Biomedicines, 2021, 9, 671.	1.4	17
47	Early Lupus Project: one-year follow-up of an Italian cohort of patients with systemic lupus erythematosus of recent onset. Lupus, 2018, 27, 1479-1488.	0.8	16
48	The role of clinically significant antiphospholipid antibodies in systemic lupus erythematosus. Reumatismo, 2016, 68, 137-143.	0.4	14
49	Inherited thrombophilia in women with poor aPLâ€related obstetric history: prevalence and outcomes. Survey of 208Âcases from the European Registry on Obstetric Antiphospholipid Syndrome cohort. American Journal of Reproductive Immunology, 2016, 76, 164-171.	1.2	14
50	Severe muscle damage with myofiber necrosis and macrophage infiltrates characterize anti-Mi2 positive dermatomyositis. Rheumatology, 2021, 60, 2916-2926.	0.9	13
51	Intrauterine fetal deaths related to antiphospholipid syndrome: a descriptive study of 65 women. Arthritis Research and Therapy, 2018, 20, 249.	1.6	12
52	Brief Report: Association of Natural Killer Cell Ligand Polymorphism HLA-C Asn80Lys With the Development of Anti-SSA/Ro-Associated Congenital Heart Block. Arthritis and Rheumatology, 2017, 69, 2170-2174.	2.9	11
53	The IMMENSE Study: The Interplay Between iMMune and ENdothelial Cells in Mediating Cardiovascular Risk in Systemic Lupus Erythematosus. Frontiers in Immunology, 2020, 11, 572876.	2.2	11
54	The limited cutaneous form of systemic sclerosis is associated with urinary incontinence: an international multicentre study. Rheumatology, 2017, 56, 1874-1883.	0.9	10

#	Article	IF	CITATIONS
55	Sine causa tetraparesis. Medicine (United States), 2018, 97, e13893.	0.4	9
56	Systematic review and meta-analysis of epidemiological studies on the association of occupational exposure to free crystalline silica and systemic lupus erythematosus. Rheumatology, 2021, 60, 81-91.	0.9	9
57	Serum IgG2 antibody multi-composition in systemic lupus erythematosus and in lupus nephritis (Part) Tj ETQq1 .	1 0,78431 0.9	.4 rgBT /Over
58	Semiquantitative analysis of line blot assay for myositis-specific and myositis-associated antibodies: a better performance?. Annals of the Rheumatic Diseases, 2020, 79, e152-e152.	0.5	8
59	Gender differences in primary antiphospholipid syndrome with vascular manifestations in 433 patients from four European centres. Clinical and Experimental Rheumatology, 2022, 40, 19-26.	0.4	8
60	Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept. Clinical and Experimental Rheumatology, 2021, 39, 91-97.	0.4	8
61	Prevalence and Diseaseâ€5pecific Risk Factors for Lower Urinary Tract Symptoms in Systemic Sclerosis: An International Multicenter Study. Arthritis Care and Research, 2018, 70, 1218-1227.	1.5	7
62	Autoantibodies' titre modulation by anti-BlyS treatment in systemic lupus erythematosus. Lupus, 2019, 28, 1074-1081.	0.8	7
63	Letter to editor: New onset/recurrence of inflammatory arthralgia/spondyloarthritis in patients treated with vedolizumab for intestinal bowel disease. Clinical Rheumatology, 2019, 38, 609-610.	1.0	6
64	An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations. Clinical Reviews in Allergy and Immunology, 2022, 63, 240-250.	2.9	6
65	A subset of systemic sclerosis but not of systemic lupus erythematosus is defined by isolated anti-Ku autoantibodies. Clinical and Experimental Rheumatology, 2013, 31, 118-21.	0.4	6
66	Managing puerperium in patients with systemic autoimmune diseases: an update. Expert Review of Clinical Immunology, 2022, 18, 391-399.	1.3	5
67	Rare clinical manifestations in systemic lupus erythematosus: a review on frequency and clinical presentation. Clinical and Experimental Rheumatology, 2022, 40, 93-102.	0.4	5
68	Anti-topoisomerase-I antibodies in systemic lupus erythematosus and potential association with the presence of anti-dsDNA antibodies. Lupus, 2017, 26, 1121-1122.	0.8	3
69	Anti-MJ/NXP-2 antibodies are the most common specifcity in a cohort of adult caucasian patients with dermatomyositis. Annals of the Rheumatic Diseases, 2012, 71, A49.2-A49.	0.5	1
70	Treatment and functional outcome of patients with cystoid macular edema: a single-center experience. Clinical Rheumatology, 2015, 34, 791-794.	1.0	1
71	Systemic Vasculitis and Pregnancy. , 2016, , 213-224.		1
72	SAT0127â€LONG-TERM OUTCOME OF CHILDREN BORN TO MOTHERS WITH CHRONIC ARTHRITIS AND EXPOS	ED	1

TO TNF-INHIBITORS DURING PREGNANCY: A CASE-CONTROL STUDY., 2019, , .

#	Article	IF	CITATIONS
73	Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept. Clinical and Experimental Rheumatology, 2021, 39, 91-97.	0.4	1
74	Use of rituximab in a multicentre cohort of patients with rheumatic diseases during the outbreak of novel SARS-COV-2 infection. Clinical and Experimental Rheumatology, 2021, 39, 695-695.	0.4	1
75	Identifying and managing lupus nephritis during pregnancy. Expert Opinion on Orphan Drugs, 2016, 4, 1021-1031.	0.5	0
76	P74â€Complement variations in systemic lupus erythematosus pregnancies. , 2020, , .		0
77	Maternal, pregnancy and neonatal outcomes of twin gestations in women with rheumatic diseases: A single-center, case-control study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 264, 49-55.	0.5	0
78	Comparative study between two European inception cohorts of patients with early systemic lupus erythematosus. Clinical and Experimental Rheumatology, 2020, 38, 925-932.	0.4	0
79	Use of rituximab in a multicentre cohort of patients with rheumatic diseases during the outbreak of novel SARS-COV-2 infection. Clinical and Experimental Rheumatology, 2021, 39, 695.	0.4	0
80	Reply to: Anti-carbamylated protein antibodies are associated with early abatacept response in rheumatoid arthritis by Castellanos-Moreira et al. Clinical and Experimental Rheumatology, 2021, 39, 1144.	0.4	0
81	Increased COVID-19 mortality in patients with rheumatic diseases: results from the CONTROL-19 study by the Italian Society for Rheumatology Clinical and Experimental Rheumatology, 2022, , .	0.4	0
82	Gender differences in primary antiphospholipid syndrome with vascular manifestations in 433 patients from four European centres Clinical and Experimental Rheumatology, 2022, , .	0.4	0